ExodusPoint Capital Management’s Entrada Therapeutics TRDA Stock Holding History

ExodusPoint Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$152K	Sell	12,067 -25,363	-68%	-$291K	﹤0.01%	1407
2025 Q4	$385K	Buy	+37,430	New	+$315K	﹤0.01%	1247
2025 Q3	–	Sell	-15,785	Closed	-$106K	–	2028
2025 Q2	$106K	Buy	+15,785	New	+$127K	﹤0.01%	1353
2025 Q1	–	Sell	-16,453	Closed	-$284K	–	1993
2024 Q4	$284K	Buy	16,453 +1,113	+7%	+$20.2K	﹤0.01%	1292
2024 Q3	$245K	Sell	15,340 -184	-1%	-$2.9K	﹤0.01%	1415
2024 Q2	$221K	Buy	+15,524	New	+$221K	﹤0.01%	1381

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's TRDA Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Entrada Therapeutics (TRDA) stake by 68% in Q1 2026, selling an estimated $291K and leaving 12,067 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

ExodusPoint Capital Management first reported a position in TRDA in Q2 2024 and has held it in 6 quarters since. The position peaked at $385K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

ExodusPoint Capital Management held 12,067 shares of Entrada Therapeutics worth $152K as of Q1 2026.
ExodusPoint Capital Management sold 25,363 Entrada Therapeutics shares in Q1 2026, an estimated $291K.
Entrada Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1407 holding.
ExodusPoint Capital Management first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 6 quarters since.
ExodusPoint Capital Management's Entrada Therapeutics position peaked at $385K in Q4 2025.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.